PL 265

Drug Profile

PL 265

Alternative Names: PL-265

Latest Information Update: 29 May 2017

Price : $50

At a glance

  • Originator Pharmaleads
  • Class Analgesics
  • Mechanism of Action Aminopeptidase inhibitors; Neprilysin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Neuropathic pain
  • Preclinical Cancer pain; Dry eyes; Ocular pain

Most Recent Events

  • 29 Jun 2017 Pharmaleads plans a phase I (multiple ascending dose) trial for Neuropathic pain in United Kingdom before 2018
  • 12 May 2017 PL 265 is available for licensing as of 12 May 2017. http://pharmalead.nl/
  • 12 May 2017 Preclinical pharmacodynamics data in Ocular pain and Dry-eye syndrome released by Pharmaleads
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top